The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review's Midwest Public Advisory Council

J Manag Care Spec Pharm. 2023 Jun;29(6):692-698. doi: 10.18553/jmcp.2023.29.6.692.

Authors

Abigail C Wright¹, Francesca L Beaudoin^{1

2}, R Brett McQueen³, Kai Yeung⁴, Ashton Moradi¹, Serina Herron-Smith¹, Eric Gutierrez³, Grace A Lin¹, Steven D Pearson¹

Affiliations

¹ Institute for Clinical and Economic Review, Boston, MA.
² Department of Epidemiology, Brown University, Providence, RI.
³ School of Pharmacy, University of Colorado, Aurora.
⁴ Kaiser Permanente Washington Health Research Institute, Seattle.

No abstract available

MeSH terms

Female
Heterocyclic Compounds, 2-Ring*
Humans
Menopause
Thiadiazoles*

Substances

fezolinetant
Heterocyclic Compounds, 2-Ring
Thiadiazoles